| [1] |
Gurusamy KS, Tsochatzis E, Toon CD. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation[J]. Cochrane Database Syst Rev, 2013, 12:CD006573. https://www.ncbi.nlm.nih.gov/pubmed/24297303
|
| [2] |
Crespo G, Mariño Z, Navasa M. Viral hepatitis in liver transplantation[J]. Gastroenterology, 2012, 142(6):1373-1383. doi: 10.1053/j.gastro.2012.02.011
|
| [3] |
Joshi D, Pinzani M, Carey I. Recurrent HCV after liver transplantation-mechanisms, assessment and therapy[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(12):710-721. doi: 10.1038/nrgastro.2014.114
|
| [4] |
AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J]. Hepatology, 2015, 62(3):932-954. doi: 10.1002/hep.27950
|
| [5] |
Jacobson IM, Gordon SC, Kowdley KV. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J]. N Engl J Med, 2013, 368(20):1867-1877. doi: 10.1056/NEJMoa1214854
|
| [6] |
Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection[J]. N Engl J Med, 2013, 369(7):678-679. doi: 10.1056/NEJMc1307641
|
| [7] |
O'Leary JG, Randall H, Onaca N. Post-liver transplant survival in hepatitis C patients is improving over time[J]. Liver Transpl, 2009, 15(4):360-368. doi: 10.1002/lt.v15:4
|
| [8] |
Burton JR Jr, O'Leary JG, Verna EC. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy[J]. J Hepatol, 2014, 61(3):508-514. doi: 10.1016/j.jhep.2014.04.037
|
| [9] |
Vitale A, Spolverato G, Burra P. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation[J]. Transpl Int, 2015, 28(9):1055-1065. doi: 10.1111/tri.2015.28.issue-9
|
| [10] |
Charlton M, Gane E, Manns MP. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation[J]. Gastroenterology, 2015, 148(1):108-117. doi: 10.1053/j.gastro.2014.10.001
|
| [11] |
Lens S, Gambato M, Londoño MC. Interferon-free regimens in the liver-transplant setting[J]. Semin Liver Dis, 2014, 34(1):58-71. doi: 10.1055/s-00000069
|
| [12] |
Welsch C, Jesudian A, Zeuzem S. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives[J]. Gut, 2012, 61(Suppl 1):i36-i46. https://www.ncbi.nlm.nih.gov/pubmed/22504918
|
| [13] |
Forns X, Charlton M, Denning J. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation[J]. Hepatology, 2015, 61(5):1485-1494. doi: 10.1002/hep.27681
|
| [14] |
Zeng QL, Zhang JY, Zhang Z. Sofosbuvir and ABT-450:terminator of hepatitis C virus?[J]. World J Gastroenterol, 2013, 19(21):3199-3206. doi: 10.3748/wjg.v19.i21.3199
|
Figures(1)
WeChat Subscription Account
Wechat Service Account
Supported by:
Beijing Renhe Information Technology Co. Ltd
DownLoad: